Clinical trials2019-12-30T21:01:28+02:00

Clinical Trials

According to the International Clinical Trials Registry Platform under the World Health Organization (WHO) and under the U.S. National Institutes of Health the following trials should be recruiting at this moment:

  • A clinical trial to assess 2 different doses of BCX7353 compared to placebo as an oral treatment for the prevention of attacks in people with HAE – recruiting in Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Ireland, the Netherlands, North Macedonia, Spain, the United Kingdom and the United States of America
  • A Long Term Safety Study of BCX7353 in HAE – recruiting in Australia, Austria, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, New Zealand, North Macedonia, Poland, Serbia, Slovakia, South Africa, South Korea, Spain,  Switzerland, the United Kingdom and the United States of America
  • A Phase 3, randomized, double-blind, placebocontrolled, parallel-group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with HAE – recruiting in Japan
  • A Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) Study of Lanadelumab to Prevent HAE Attacks in Pediatric Participants of 2 Years to Less Than (<) 12 Years of Age – recruiting in Canada, Germany, Hungary, Spain and the United States of America
  • A study to a) evaluate the tolerability and blood levels of KVD900 when given as a single dose to patients and b) to assess whether KVD900 is effective in treating attacks of swelling in patients with the genetic disease HAE – recruiting in Austria, Germany, Hungary, the Netherlands, North Macedonia and the United Kingdom
  • A Study to Assess the Clinical Efficacy of IONIS-PKKLRx in Participants with HAE – recruiting in the United States of America
  • A Study to Investigate CSL312 in Subjects with HAE – recruiting in Australia, Canada, Germany, Israel, and the United States of America
  • Biomarker for HAE Disease Type 1 (BioHAE) – recruiting in Egypt, Georgia, Germany and India
  • Cloud-R HAE Registry – recruiting in France
  • C1 Inhibitor Registry in the Treatment of HAE Attacks – recruiting in Bulgaria, Croatia, Czech Republic, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia and Sweden
  • Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population – recruiting in France
  • Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants with HAE – recruiting in Japan
  • Epidemiological Analysis for HAE Disease – recruiting in Germany, Italy, Poland, Turkey and the United Kingdom
  • Firazyr General Drug Use-Results Survey (Japan) – recruiting in Japan
  • Firazyr Patient Registry (Icatibant Outcome Survey – IOS) – recruiting in Australia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Spain, Sweden and the United Kingdom
  • Global Registry to Gather Data on Natural History of Patients with HAE Type I and II – recruiting in Italy
  • HAE Kininogen Assay – recruiting in Germany
  • Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients with Hereditary Bradykinetic Angioedema – recruiting in France
  • Lanadelumab tested in patients suffering from HAE with normal C1-Inhibitor – recruiting in Germany
  • Pathophysiological study for autoimmune dysregulation of HAE – recruiting in Japan
  • Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency – recruiting in Italy
  • Patient Registry to Evaluate the Real-world Safety of Ruconest – recruiting in the United States of America
  • Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants with HAE – recruiting in Canada, Puerto Rico and the United States of America
  • The Role of the Coagulation Pathways in Recurrent Angioedema – recruiting in France
  • Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants with HAE – will be recruiting Austria, Germany and Switzerland

Read more about these and other clinical trials at and

HAE related topics that might interest you

Global Access Program

Helping to change the lives of patients with hereditary angioedema (HAE) with a medication access program

Global Perspectives

Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community

HAEi Connect Member database

Free, secure online membership database and communications platform for HAEi’s member organizations

Regional Patient Advocates

Constantly strive to improve the situation for HAE friends all over the world – no matter how they are organized

Stay tuned – sign up for our newsletter


Click here to sign up

HAE Global Conference 2018

This 4th HAE conference was record breaking: A total of 736 patients and care givers participated from no less than 57 countries

HAEi hosted websites

Hosting of your national website or help for you to create a new website – naturally all in your native language